Cyted Health Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
74
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$43.8M
- Investors
-
11
Cyted Health General Information
Description
Developer of non-endoscopic diagnostic technology designed for the early detection of esophageal diseases and cancer. The company's minimally invasive capsule sponge device, combined with advanced molecular diagnostics, enables safe and accessible esophageal cell collection in community settings, helping clinicians identify precursors like Barrett's Esophagus and move patients toward earlier treatment.
Contact Information
Website
www.cytedhealth.comCorporate Office
- Ground floor Building 3
- Old Swiss, 149 Cherry Hinton Road
- Cambridge CB1 7BX
- England, United Kingdom
Corporate Office
- Ground floor Building 3
- Old Swiss, 149 Cherry Hinton Road
- Cambridge CB1 7BX
- England, United Kingdom
Cyted Health Timeline
Cyted Health Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B) | 29-Aug-2025 | $43.8M | Completed | Generating Revenue | ||
| 6. Accelerator/Incubator | 01-Jan-2024 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 18-May-2023 | Completed | Generating Revenue | |||
| 4. Grant | 28-Apr-2023 | Completed | Generating Revenue | |||
| 3. Grant | 03-May-2022 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 01-Feb-2020 | $11.4M | $11.4M | Completed | Generating Revenue | |
| 1. University Spin-Out | 23-Jul-2018 | Completed | Startup |
Cyted Health Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B1 | ||||||||
| Series B | ||||||||
| Series A 1 | ||||||||
| Series A 1 | ||||||||
| Ordinary | 202,080 | $0.001344 | $4.21 | $4.21 | 1x | $4.21 | 1.63% | |
| Series A | 2,396,158 | $0.001344 | $4.21 | $4.21 | 1x | $4.21 | 19.37% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cyted Health Comparisons
Industry
Financing
Details
Cyted Health Competitors (3)
One of Cyted Health’s 3 competitors is TytoCare, a Venture Capital-Backed company based in Netanya, Israel.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TytoCare | Venture Capital-Backed | Netanya, Israel | ||||
| Gene By Gene | Formerly VC-backed | Houston, TX | ||||
| Ava (Monitoring Equipment) | Formerly VC-backed | Zurich, Switzerland |
Cyted Health Patents
Cyted Health Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202408601-D0 | Training apparatus for oesophageal cell collection, and method for use thereof | Active | 14-Jun-2024 | ||
| GB-2641895-A | Training apparatus for oesophageal cell collection, and method for use thereof | Active | 14-Jun-2024 | ||
| GB-2641895-B | Training apparatus for oesophageal cell collection, and method for use thereof | Active | 14-Jun-2024 | ||
| GB-202316758-D0 | Diagnostic methods | Inactive | 01-Nov-2023 | ||
| AU-2024336290-A1 | A device for collecting cells with alternating wound retrieval thread | Pending | 07-Sep-2023 | A61B10/02 |
Cyted Health Signals
Cyted Health Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advent Life Sciences | Venture Capital | Minority | ||
| British Business Bank | Lender/Debt Provider | Minority | ||
| EQT Life Sciences | Venture Capital | Minority | ||
| MedTech Innovator | Accelerator/Incubator | |||
| BGF (Financial Services) | Growth/Expansion | Minority |
Cyted Health Acquisitions (1)
Cyted Health’s most recent deal was a Merger/Acquisition with Pathognomics. The deal was made on 19-Oct-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pathognomics | 19-Oct-2020 | Merger/Acquisition | Laboratory Services (Healthcare) |
Cyted Health FAQs
-
When was Cyted Health founded?
Cyted Health was founded in 2018.
-
Where is Cyted Health headquartered?
Cyted Health is headquartered in Cambridge, United Kingdom.
-
What is the size of Cyted Health?
Cyted Health has 74 total employees.
-
What industry is Cyted Health in?
Cyted Health’s primary industry is Diagnostic Equipment.
-
Is Cyted Health a private or public company?
Cyted Health is a Private company.
-
What is the current valuation of Cyted Health?
The current valuation of Cyted Health is .
-
What is Cyted Health’s current revenue?
The current revenue for Cyted Health is .
-
How much funding has Cyted Health raised over time?
Cyted Health has raised $67.9M.
-
Who are Cyted Health’s investors?
Advent Life Sciences, British Business Bank, EQT Life Sciences, MedTech Innovator, and BGF (Financial Services) are 5 of 11 investors who have invested in Cyted Health.
-
Who are Cyted Health’s competitors?
TytoCare, Gene By Gene, and Ava (Monitoring Equipment) are competitors of Cyted Health.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process